Clinical

Dataset Information

0

Prospective cohort study of optimal discontinuation of oxaliplatin in elderly patients treated with XELOX plus bevacizumab


ABSTRACT: Interventions: XELOX+BEV Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Bevacizumab:7.5mg/kg d1 Q3w Discontinuation of oxaliplatin when neurotoxicity develops >=Grade2 Primary outcome(s): Rate of Grade3 neuropathy Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631347 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2623439 | ecrin-mdr-crc
| 2687981 | ecrin-mdr-crc
| 89641 | ecrin-mdr-crc
| 2619445 | ecrin-mdr-crc
| 2673059 | ecrin-mdr-crc
2010-11-24 | E-GEOD-23874 | biostudies-arrayexpress
| 2619574 | ecrin-mdr-crc
| 2404460 | ecrin-mdr-crc
| 2620327 | ecrin-mdr-crc
| 2621009 | ecrin-mdr-crc